Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Septerna
AddedFeb 13, 2024
UpdatedJun 18, 2026
Septerna

Septerna

Series B

Septerna: A biotech firm pioneering novel small molecule medicines for future patient care.

HQ
San Francisco, CA, US
Founded
2022
Overview
Compare
Fundraising
Employees
Website

Septerna, founded with the mission to revolutionize GPCR drug discovery, focuses on creating novel small molecule medicines to address unmet medical needs. Utilizing their proprietary Native Complex Platform™, Septerna aims to unlock the therapeutic potential of G protein-coupled receptors (GPCRs), which play a crucial role in regulating various physiological processes. The company targets a broad market within the biotechnology and pharmaceutical sectors, striving to bring innovative treatments to patients.

Notable figures associated with Septerna include leading scientists and industry veterans who bring extensive expertise in drug discovery and development. The company has garnered significant attention and investment from prominent venture capital firms, underscoring its potential impact. Key achievements include advancing their platform technology and progressing multiple drug candidates through early development stages. Septerna's work promises to significantly impact future medical treatments by harnessing the power of GPCRs.

Septerna - Similar Companies

Seven Biosciences logo

Seven Biosciences

Octant logo

Octant

octant.bio

Epiodyne logo

Epiodyne

Empirico logo

Empirico

empiricotx.com

Curie.Bio logo

Curie.Bio

curie.bio

BlueLight Therapeutics logo

BlueLight Therapeutics

bluelighttx.com

Mebias Discovery logo

Mebias Discovery

Generian Pharmaceuticals logo

Generian Pharmaceuticals

generian.com

Deep Apple Therapeutics logo

Deep Apple Therapeutics

deepappletx.com

Selonterra logo

Selonterra

selonterra.com

Juvena Therapeutics logo

Juvena Therapeutics

Cryptyx Bioscience logo

Cryptyx Bioscience

Atavistik Bio logo

Atavistik Bio

atavistikbio.com

Capienda Biotech logo

Capienda Biotech

capienda.us

Seranova Bio logo

Seranova Bio

seranovabio.com

Septerna - Quick Facts

Who are Septerna's competitors?

Companies similar to Septerna include Seven Biosciences, Octant, Epiodyne and Empirico.

When was Septerna founded?

Septerna was founded in 2022.

Where is Septerna's headquarters located?

Septerna's headquarters is located in San Francisco, CA, US.

When was Septerna's last funding round?

Septerna's most recent funding round was for $150M (USD) in July 2023.

How much has Septerna raised to-date?

As of Jul 11, 2023, Septerna has raised a total of $250M (USD).

How many employees does Septerna have?

Septerna has 50 employees as of Feb 5, 2024.

Septerna - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Small Molecule Drugs
Tags
  • SaaS
Unique IDs
  • ein: 843891440
  • secCik: 0001984086
  • ticker: SEPN
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software